MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.230
+0.030
+0.94%
Closed 16:00 11/15 EST
OPEN
3.280
PREV CLOSE
3.200
HIGH
3.304
LOW
3.180
VOLUME
23.29K
TURNOVER
--
52 WEEK HIGH
11.90
52 WEEK LOW
3.170
MARKET CAP
50.75M
P/E (TTM)
-1.2414
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PSTI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PSTI News

  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.1d ago
  • Pluristem Therapeutics CEO Issues Shareholder Update
  • GlobeNewswire.3d ago
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.11/08 13:16
  • RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare
  • GlobeNewswire.11/04 12:00

More

Industry

Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About PSTI

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
More

Webull offers Pluristem Therapeutics Inc. (PSTI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.